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Abstract
In 2016, 91 countries reported a total of 216 million cases of malaria, an increase of 5 mil-
lion cases over the previous year, and the estimated malaria deaths worldwide were 
445,000 like in 2015. This suggests that despite a substantial reduction in the malaria bur-
den observed since 2010, largely attributed to the scale-up of effective control measures 
(vector control interventions, efficacious antimalarial treatment), the rate of decline of both 
clinical cases and malaria deaths has stalled since 2014 and in some regions even reversed. 
Achieving universal access to standard control interventions, such as case management, 
implementation of vector control methods, seasonal malaria chemoprevention, and inter-
mittent preventive treatment for pregnant women, remains a priority. It is essential to 
contain emerging drug resistance in malarial parasite and insecticide resistance in mos-
quito vector species. Additional new interventions to accelerate interruption of transmis-
sion are in crucial need for their rapid integration within the standard control activities. 
These integrated control approaches must be implemented at community level with the 
active involvement of the local populations to reach high coverage. Finally, political and 
financial supports should be maintained and even doubled to reach the 2030 targets of the 
WHO global technical strategy for malaria.
Keywords: malaria elimination, mass drug administration, drug resistance, insecticide 
resistance
1. Introduction
In 2016, 91 countries reported a total of 216 million cases of malaria, an increase of 5 mil-
lion cases over the previous year. The estimated number of malaria deaths worldwide was 
445,000, about the same number reported in 2015 [1]. This suggests that, despite a substan-
tial reduction in the malaria burden observed since 2010, largely attributed to the scale-up 
of effective control measures, including vector control interventions and treatment with 
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 efficacious antimalarial medicines, the rate of decline of both clinical cases and malaria 
deaths has stalled since 2014 and in some regions (the Americas mainly and marginally 
in the Southeast Asia, Western Pacific, and African regions) even reversed [1]. The World 
Health Organization (WHO) has estimated that to meet the 2030 targets of global malaria 
strategy, a minimum investment of US$ 6.5 billion per year by 2020 is required [2]. In 2016, 
such investment was US$ 2.7 billion, less than half of that required amount, and since 2014 in 
many high-burden countries, investments in malaria control have declined [1]. The call for 
malaria eradication launched at the Malaria Forum in October 2007 by the Bill & Melinda 
Gates Foundation and then supported by the WHO, Roll Back Malaria (RBM) Partnership, 
and many other organizations and institutions seems to be at crossroads [3].
2. Components of malaria elimination strategy
The WHO currently considers malaria elimination at the national level as a continuum rather 
than the achievement of milestones for specific phases [2]. It is structured in 4 components 
(A–D), each of them to be implemented according to the malaria transmission intensity. 
Component “A” consists of enhancing and optimizing vector control and case management, 
which includes universal access to malaria preventions, diagnosis, and treatment for at-risk 
populations, and once elimination has been achieved, “focalized” vector control programs 
rather than scaling back these activities; component “B” aims at increasing the sensitivity 
and specificity of surveillance to detect, characterize, and monitor all cases (individual and 
in foci), namely, to transform malaria surveillance into a core intervention; component “C” 
aims at accelerating transmission reduction in which new interventions such as mass drug 
administration (MDA) or new vaccines are included; and component “D” is implemented 
when transmission intensity is low to very low, which includes the search for the few remain-
ing infections and any foci of ongoing transmission, clearing them with appropriate treatment 
and possibly additional vector control activities [2].
3. Resistance of Plasmodium falciparum to anti-malaria drugs
Resistance to first-line treatments for Plasmodium falciparum malaria and to the insecticides 
used for Anopheles vector control is threatening malaria elimination efforts [4]. Artemisinin 
and its derivatives provide the fastest parasite clearance among available antimalarial drugs 
and have been combined with an antimalarial drug of a different class in order to (i) enhance 
complete cure rates, (ii) shorten the duration of therapy for artemisinin monotherapies, and 
(iii) delay the selection and spread of resistant parasites [5, 6]. Artemisinin-based combination 
treatments (ACTs) are currently recommended for the management of uncomplicated malaria 
cases. In 2007, the first cases of delayed parasite clearance, suggesting artemisinin resistance, 
were observed at the Thailand-Cambodia border [7, 8]. Artemisinin resistance has now been 
reported in 5 countries of the Greater Mekong Subregion (GMS), which includes Cambodia, 
Myanmar, Laos, Thailand, and Vietnam, and delayed parasite clearance has been linked to 
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point mutations in the propeller region of a P. falciparum protein gene on chromosome 13 
(K13) [9]. Artemisinin resistance may have spread to or emerged in Bangladesh [10] and has 
extended across much of Myanmar with a high prevalence of P. falciparum parasites carrying 
K13-propeller mutations reported next to the north-western border of India [11]. Resistance 
may have also emerged in South America, including Guyana, Suriname, French Guiana, and 
bordering areas of Brazil and Venezuela, [12, 13] that shares several characteristics with the 
GMS, increasing the risk of selecting resistant parasites. These include higher P. falciparum 
transmission than the rest of the Amazon Basin, highly mobile populations, availability and 
widespread use of several antimalarial drugs of questionable quality, including artemisinin 
monotherapies, and poor access and use of formal malaria diagnostic and treatment facili-
ties [14]. Besides artemisinin resistance, the prevalence of molecular markers correlated to 
resistance to the partner drugs has increased. For example, changes in the prevalence of pfcrt 
and pfmdr1 alleles have been observed in many areas where ACTs including amodiaquine or 
lumefantrine have been intensively used [4]. However, outside the GMS, recommended ACTs’ 
efficacy remains acceptable (4). In Southeast Asia, the intensive use of dihydroartemisinin-
piperaquine (DP) has resulted in selection of parasites with multiple resistance mechanisms, 
and in Cambodia high levels of treatment failure to DP are now observed [15]. Resistance to 
piperaquine (clinical and in vitro) may be associated to plasmepsins 2–3, but other markers 
could be involved [4].
4. Resistance of Anopheles mosquito vectors to insecticides
Resistance of malaria vectors to the 4 insecticide classes (pyrethroids, organochlorines, 
organophosphates, and carbamates) used for vector control interventions threatens malaria 
prevention and control efforts. Of the 76 malaria endemic countries that reported standard 
monitoring data from 2010 to 2016, resistance was detected in 61 countries to at least one 
insecticide in one malaria vector from one collection site, and 50 countries had resistance 
to 2 or more insecticides [1]. Resistance to pyrethroids, insecticides used in all long-lasting 
insecticidal nets (LLINs), is widespread though its impact on LLIN effectiveness is unclear 
[16]. There was no association between malaria disease burden and the level of resistance in 
a WHO-coordinated study implemented in 5 countries (Sudan, Kenya, India, Cameroon, and 
Benin) [1]. However, given the complexity in measuring the impact of insecticide resistance, it 
is not possible to equate lack of evidence of impact with evidence for no impact [16].
5. Asymptomatic malaria infections and mass drug administration 
(MDA)
One of the major problems to achieve malaria elimination is represented by the hidden parasite 
reservoir in the human host. Microscopy (and rapid diagnostic tests (RDTs)) underestimates 
by about half the prevalence of Plasmodium infection, and this difference is greatest in low-
transmission settings—many asymptomatic infections can persist for significant periods of 
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time. The presence of P. falciparum gametocytes is positively associated with the absence of 
clinical symptoms and low asexual parasite densities; mosquitoes can become infected with 
gametocyte densities as low as 5 gametocytes/μl and theoretically as low as one gameto-
cyte/μl—children with undetectable gametocytaemia by molecular methods were still 
observed to be infectious to mosquitoes [17]. To accelerate achieving malaria elimination, 
the human reservoir of infection needs to be tackled with new approaches. There is a grow-
ing interest in MDA of at-risk populations or in malaria hot-spot areas with an effective 
antimalarial to reduce the parasite reservoir in human host [18]. MDA aims to provide full 
post-treatment courses to the whole population to clear asymptomatic infections and pro-
vide posttreatment prophylaxis to prevent reinfection. The use of MDA is recommended 
in areas approaching interruption of transmission, with good access to treatment, effective 
vector control, and surveillance systems, ensuring a minimal risk of reintroduction of infec-
tion [19]. MDAs have been conducted using a variety of drug regimens at different dos-
ages, timings, and frequency. There is evidence of substantial but short-lived reduction in 
P. falciparum parasite carriage [20]. In Zambia, a cluster-randomized control trial imple-
mented in a population of 330,000 individuals, distributed in 56,000 households, compared 
MDA with DP (2 rounds), at the household level (DP to all members of household with at 
least a RDT-positive individual) and standard control measures (case management, LLIN, 
indoor residual spraying (IRS), and intermittent preventive treatment during pregnancy). 
MDA decreased significantly malaria prevalence and incidence in low (malaria prevalence 
<10%) but not in high (malaria prevalence ≥10%) transmission areas [21]. With the grow-
ing awareness of heterogeneity and clustering in transmission, MDA approaches have been 
modified by systematic (mass screening and treatment) or focused (focal screening and treat-
ment) screening and treatment of populations in defined geographical areas. Reactive case 
detection, i.e., screening and treating positive contacts in response to a clinical event, has been 
tested and implemented in some countries [22–25]. However, its impact has been variable as 
it is affected by the sensitivity of the diagnostic tool and the radius of intervention around a 
clinical case [26–29].
The antimalarial treatment administered during MDA campaigns could be complemented 
by single low-dose of primaquine, an 8-aminoquinoline that is able to clear mature P. falci-
parum gametocytes [30], and/or ivermectin, a systemic endectocidal drug that can be admin-
istered safely to both humans and animals but proven toxic to Anopheles mosquitoes when 
they take a blood meal from a host that has recently received the drug [31, 32]. Primaquine 
may cause a dose-dependent hemolysis, mainly in individuals with deficiency of the 
enzyme glucose 6-phosphate dehydrogenase (G6PD) in red blood cells [33], and this has 
slowed down its implementation. Nevertheless, a single low-dose of primaquine can sig-
nificantly reduce gametocyte carriage in both symptomatic [33] and asymptomatic [34] indi-
viduals and reduces onward transmission from man to vector [35]. Ivermectin can be safely 
administered with an ACT [36, 37] and has been used widely against parasitic diseases 
in humans, with record of more than 2 billion doses in MDA campaigns against onchocer-
ciasis and lymphatic filariasis. In Burkina Faso, Liberia, and Senegal, one round of MDA 
with ivermectin at the standard dose of 150 μg/kg decreased substantially An. gambiae sur-
vival for 6 days and reduced the proportion of sporozoite-positive (infectious) mosquitoes 
for 2 weeks [38]. However, evidence of ivermectin as an additional tool to decrease malaria 
transmission is limited and needs to be further quantified, possibly by a cluster randomized 
Towards Malaria Elimination - A Leap Forward6
trial in a country with high coverage of standard control interventions and substantial residual 
malaria transmission.
6. Conclusions
In conclusion, achieving universal access to standard control interventions, namely, case 
management, LLIN, IRS, seasonal malaria chemoprevention, and intermittent preventive 
treatment for pregnant women, remains a priority. It is essential to contain emerging drug 
resistance in malarial parasite and insecticide resistance in mosquito vector species. There is 
a dire need of additional new interventions to accelerate interruption of transmission. These 
should be evaluated and rapidly integrated within the standard control activities. Most of 
these should be implemented at the community level, and it will be important to actively 
involve the local populations to reach high coverage. Finally, political and financial supports 
should be maintained and even increased; current financial support is less than half of that 
estimated to reach the 2030 targets of the WHO global technical strategy for malaria [1].
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